Literature DB >> 20829819

Oncology's energetic pipeline.

Ken Garber.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20829819     DOI： 10.1038/nbt0910-888

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  12 in total

1.  Industry makes strides in melanoma.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2010-08       Impact factor: 54.908

2.  Pyruvate kinase M2 is a phosphotyrosine-binding protein.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Ning Wu; John M Asara; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

3.  Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.

Authors:  Jihye Yun; Carlo Rago; Ian Cheong; Ray Pagliarini; Philipp Angenendt; Harith Rajagopalan; Kerstin Schmidt; James K V Willson; Sandy Markowitz; Shibin Zhou; Luis A Diaz; Victor E Velculescu; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos
Journal:  Science       Date:  2009-08-06       Impact factor: 47.728

4.  Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.

Authors:  Andrew Y Choo; Sang Gyun Kim; Matthew G Vander Heiden; Sarah J Mahoney; Hieu Vu; Sang-Oh Yoon; Lewis C Cantley; John Blenis
Journal:  Mol Cell       Date:  2010-05-28       Impact factor: 17.970

5.  c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.

Authors:  Ping Gao; Irina Tchernyshyov; Tsung-Cheng Chang; Yun-Sil Lee; Kayoko Kita; Takafumi Ochi; Karen I Zeller; Angelo M De Marzo; Jennifer E Van Eyk; Joshua T Mendell; Chi V Dang
Journal:  Nature       Date:  2009-02-15       Impact factor: 49.962

6.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

7.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

8.  Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis.

Authors:  Ralph J DeBerardinis; Anthony Mancuso; Evgueni Daikhin; Ilana Nissim; Marc Yudkoff; Suzanne Wehrli; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-21       Impact factor: 11.205

9.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

Review 10.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.

Authors:  E D Michelakis; L Webster; J R Mackey
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640
View more
  7 in total

1.  Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism.

Authors:  K Thangavelu; Catherine Qiurong Pan; Tobias Karlberg; Ganapathy Balaji; Mahesh Uttamchandani; Valiyaveettil Suresh; Herwig Schüler; Boon Chuan Low; J Sivaraman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-26       Impact factor: 11.205

2.  Spectrum of somatic mitochondrial mutations in five cancers.

Authors:  Tatianna C Larman; Steven R DePalma; Angela G Hadjipanayis; Alexei Protopopov; Jianhua Zhang; Stacey B Gabriel; Lynda Chin; Christine E Seidman; Raju Kucherlapati; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

3.  First metabolic oncology inhibitor gets FDA green light, with record price tag.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2017-10-11       Impact factor: 68.164

4.  Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA).

Authors:  K Thangavelu; Qing Yun Chong; Boon Chuan Low; J Sivaraman
Journal:  Sci Rep       Date:  2014-01-23       Impact factor: 4.379

5.  ¹H NMR and hyperpolarized ¹³C NMR assays of pyruvate-lactate: a comparative study.

Authors:  Deborah K Hill; Yann Jamin; Matthew R Orton; Nicolas Tardif; Harold G Parkes; Simon P Robinson; Martin O Leach; Yuen-Li Chung; Thomas R Eykyn
Journal:  NMR Biomed       Date:  2013-05-27       Impact factor: 4.044

6.  PDK1 inhibition is a novel therapeutic target in multiple myeloma.

Authors:  S Fujiwara; Y Kawano; H Yuki; Y Okuno; K Nosaka; H Mitsuya; H Hata
Journal:  Br J Cancer       Date:  2012-11-29       Impact factor: 7.640

7.  Targeting of two aspects of metabolism in breast cancer treatment.

Authors:  Bevan P Gang; Pierre J Dilda; Phillip J Hogg; Anneke C Blackburn
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.